Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124490 | 0.87 | BACE1 (0.39) | BACE1KMT2ASLC22A12CYP2C9CYP2C19 | |
| SCHEMBL14124471 | 0.82 | IDO1 (0.41) | BACE1KMT2ASLC22A12CYP2C9CYP2C19 | |
| SCHEMBL14124487 | 0.82 | IDO1 (0.41) | BACE1KMT2ASLC22A12CYP2C9CYP2C19 | |
| SCHEMBL10041271 | 0.81 | TSHR (0.42) | SLC22A12GAA | |
| SCHEMBL15746018 | 0.80 | BACE1 (0.42) | BACE1KMT2ASLC22A12CYP2C19NPC1 | |
| SCHEMBL10041264 | 0.76 | BACE1 (0.35) | BACE1KMT2ASLC22A12CYP2C19NPC1 | |
| SCHEMBL14124504 | 0.75 | IDO1 (0.39) | BACE1KMT2ASLC22A12BRD4PDE2A | |
| SCHEMBL14124492 | 0.73 | CCNB2 (0.32) | — | |
| SCHEMBL6489159 | 0.70 | HTR3E (0.40) | BACE1KMT2ANPC1RAB9APDE2A | |
| SCHEMBL14124473 | 0.70 | CNR2 (0.38) | SLC22A12RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147987-B2 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8147987-B2 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | RPL31, RPL38, RPL39 | BACE1 2152/4885KMT2A 1256/4885SLC22A12 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.